Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 894416 in male asthma patients
NCT03971539Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 894416 in asthma (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Patients With Treatment-emergent Adverse Events Related to BI 894416 up to 30 days. Started Jul 2019; status: completed.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03971539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971539.